about
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionalityA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroBuilding collaborative networks for HIV/AIDS vaccine development: the AVIP experience.Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment.The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes.Short communication: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in AfricaA nonsense mutation (428G-->A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection.DNA mucosal HIV vaccine in humans.Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody.HIV subtypes and recombination strains--strategies for induction of immune responses in man.Therapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC)HIV immunology better understood and vaccination attempts started.Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporationPotent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.Sexually transmitted herpes simplex viruses.Therapeutic vaccination against HIV.Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology.Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.DNA vaccines: progress and challenges.Gene-based vaccines: recent technical and clinical advances.A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines.Therapeutic immunization for HIV.DNA vaccines: recent developments and future possibilities.Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunityBroad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.Vaccine delivery methods using viral vectors.Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.Murine models for HIV vaccination and challenge.DNA vaccines for HIV/AIDS.Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda.Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.
P50
Q24794430-762A282B-2707-4902-81A1-E1825BDCD02FQ28728917-9D9C529C-4BEF-43A9-A59C-3CEE9C543EB3Q30356937-E10671DC-A885-4D25-BA85-6AE75F4E91C7Q33507532-4C09D991-08D7-4C2D-B544-68F25BA8CC3FQ33788780-59B05B75-16A0-4BEE-B3AB-17683C54B23DQ33962664-22AEE54E-D794-46D4-8A3D-35913137F635Q34399680-ABF6994A-63B4-45C3-A76C-99E55A5A2284Q34499326-EEBAAAE1-A755-4BF4-91AA-A8BF210E8E83Q34556298-AD10F47E-D9EC-46EA-8808-326A94EDC06AQ34567557-D699D675-65A6-4655-AB6D-7D2C55BA21E9Q34619939-91BC553F-6434-45C9-BC0B-38BFBBCC9A91Q35060232-45E88825-B21F-4791-A654-50568EBA671EQ35108702-6C799A9F-3F9E-4E5C-B83F-9EE67BE5984FQ35191236-3DAD4E47-DD1A-47CC-8884-8B6E5FCB9FE8Q35415717-2C63899E-C3BB-42F7-9FDD-0486D2B3A8A2Q35431516-A31B813A-B83D-4AB3-B43C-3D98E7591F8CQ35475930-94DE5484-5DC7-439C-B2A9-92D3F4EB90EEQ35677513-0E6F56E1-0BA7-4A96-9755-934CBA9EAB27Q35733995-FAF114C1-77BD-4B2E-8AED-75B4F50C78EAQ35851825-1B4D0F13-F1F0-4CE7-A0B3-C118C755E337Q35995081-EB10770C-6E91-4023-A248-001D5B523B9CQ36017750-43273588-C558-4E2B-8442-56C9D463BBABQ36021144-5C2F7208-0138-4B62-A409-554E7D77BC14Q36186005-8D4B6FFF-DF3F-4276-AA0C-E50916BD829BQ36452337-7403C903-6D44-4CBF-95BD-E566E3B7192AQ36494079-1D8DA5FB-E368-43FB-94BC-6619AF4BDE7EQ36619422-4E761D42-AA26-420A-8D95-1613BB8C94FFQ36619614-240648E4-830E-4844-80C7-FA8F978E2AD2Q36679394-28B22A7C-2EAA-4192-91A2-B89D40357788Q36692389-426EB255-A44A-41C7-A3E9-613A1BE94053Q36697992-31148086-8A29-49EA-9F46-7C300DE8CE9EQ36726667-A5B6CB11-C838-4FC4-87F3-6A9E51118D39Q37015233-45665021-8DE4-49E9-B04E-AD7D0DDB7369Q37077665-50172768-836E-4979-9238-5E1B1FAA966EQ37446967-B1912EEA-C0E4-4F8D-AC20-F4AE546173CBQ37610683-32499A79-322D-4A18-BE57-6603590A6FCDQ38884220-59BF5DAE-CC7C-4192-AE64-3DDF2F41D84AQ38897238-D6C29D9D-03A0-4276-BB95-D489B1DF6339Q39834304-0E6E505B-9E8E-4E51-8EEB-E23A7CA3792EQ39981110-7CB769B9-7107-4A3D-B9F3-484A8DE83A4E
P50
name
Britta Wahren
@br
Britta Wahren
@co
Britta Wahren
@da
Britta Wahren
@de
Britta Wahren
@en
Britta Wahren
@es
Britta Wahren
@fr
Britta Wahren
@id
Britta Wahren
@it
Britta Wahren
@nds
type
label
Britta Wahren
@br
Britta Wahren
@co
Britta Wahren
@da
Britta Wahren
@de
Britta Wahren
@en
Britta Wahren
@es
Britta Wahren
@fr
Britta Wahren
@id
Britta Wahren
@it
Britta Wahren
@nds
prefLabel
Britta Wahren
@br
Britta Wahren
@co
Britta Wahren
@da
Britta Wahren
@de
Britta Wahren
@en
Britta Wahren
@es
Britta Wahren
@fr
Britta Wahren
@id
Britta Wahren
@it
Britta Wahren
@nds